Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Cacciatore S, Wium M, Licari C, Ajayi-Smith A, Masieri L, Anderson C, et al. Inflammatory metabolic profile of South African patients with prostate cancer. Cancer Metab. 2021;9(1):29.

Weiner AB, Vidotto T, Liu Y, Mendes AA, Salles DC, Faisal FA, et al. Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. Nat Commun. 2021;12(1):935.

Han Y, Duan X, Yang L, Nilsson-Payant BE, Wang P, Duan F, et al. Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature. 2021;589(7841):270-275.

Yang HS, Hou Y, Zhang H, Chadburn A, Westblade LF, Fedeli R, et al. Machine Learning Highlights Downtrending of COVID-19 Patients with a Distinct Laboratory Profile. Health Data Sci. 2021;2021:7574903.

Kubiak J, Davidson E, Soave R, Kodiyanplakkal RP, Robertson A, van Besien K, et al. Colonization with Gastrointestinal Pathogens Prior to Hematopoietic Cell Transplantation and Associated Clinical Implications. Transplant Cell Ther. 2021;27(6):499.e1-499.e6.

Marzo F, Milagro FI, Barrenetxe J, Díaz MT, J Martínez A. Azoxymethane-Induced Colorectal Cancer Mice Treated with a Polyphenol-Rich Apple Extract Show Less Neoplastic Lesions and Signs of Cachexia. Foods. 2021;10(4).

Romero-Velez G, Pereira X, Yang J, Panarelli NC, McAuliffe JC. Neuroendocrine Tumor of the Common Bile Duct Associated With von Hippel-Lindau Disease. ACG Case Rep J. 2021;8(2):e00512.

Centenera MM, Scott JS, Machiels J, Nassar ZD, Miller DC, Zinonos I, et al. ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. Cancer Res. 2021;81(7):1704-1718.

Schienda J, Church AJ, Corson LB, Decker B, Clinton CM, Manning DK, et al. Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol. 2021;5.

Tang X-, Melis M, Lu C, Rappa A, Zhang T, Jessurun J, et al. A retinoic acid receptor β2 agonist attenuates transcriptome and metabolome changes underlying nonalcohol-associated fatty liver disease. J Biol Chem. 2021;297(6):101331.